From: Genetic characterisation of molecular targets in carcinoma of unknown primary
Sample ID | Anatomical location | Morphology | Gender | Age | % of tumour cellularity | Sampling method | Gene | Amino acid change | Copy number detected | Allele ratio | Detected by both Panels | Actionable target |
---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | Lymph node (cervical) | SCC | F | 62 | 80 | TS | TP53 | G245D | 0.79 | |||
CCND1 | 12.31 | Yes | ||||||||||
FGFR1 | 8.31 | Yes | ||||||||||
MYC | 10 | Yes | ||||||||||
2 | Lymph node (inguinal) | SCC | M | 67 | 90 | TS | TP53 | I195N | 0.13 | |||
3 | Lymph node (inguinal) | SCC | F | 51 | 100 | Macro | CDKN2A | D74N | 0.35 | |||
PIK3CA | E545K | 0.17 | Yes | Yes | ||||||||
4 | Lymph node (mesenteric) | PD Carcinoma | F | 81 | 100 | LCM | BRAF | V600E | 0.22 | Yes | Yes | |
5 | Maxillary sinus | SCC | F | 79 | 90 | TS | TP53 | R248W | 0.23 | |||
TP53 | P177L | 0.29 | ||||||||||
ERBB2 | S310F | 0.28 | Yes | |||||||||
6 | Parotid | SCC | M | 54 | 100 | Macro | TP53 | E286K | 0.08 | |||
7 | Skin | Neuroendocrine Ca | F | 81 | 95 | TS | MET | R988C | 0.4 | Yes | ||
8 | Submandibular gland | SCC | M | 81 | 95 | TS | MYC | 6.97 | Yes | |||
9 | Bone | PD Carcinoma | F | 80 | 50 | TS | MET | T1010I | 0.49 | Yes | Yes | |
10 | Bone | Adenocarcinoma | M | 71 | 100 | LCM | KRAS | G12D | 0.67 | Yes | Yes | |
11 | Lymph node (axillary) | Adenocarcinoma | F | 82 | 80 | TS | TP53 | Q165Ter | 0.51 | |||
12 | Omentum | Adenocarcinoma | F | 68 | 100 | LCM | TP53 | R175H | 0.75 | |||
13 | Parotid | SCC | M | 79 | 100 | Macro | TP53 | S241F | 0.28 | |||
TP53 | P152L | 0.22 | ||||||||||
14 | Parotid | PD Carcinoma | F | 76 | 100 | Macro | HRAS | G13N | 0.51 | Yes | Yes | |
HRAS | G13S | 0.51 | Yes | Yes | ||||||||
15 | Thyroid | SCC | F | 80 | 100 | Macro | MLH1 | V384D | 0.5 | |||
BRAF | V600E | 0.12 | Yes | Yes | ||||||||
16 | Brain | PD Carcinoma | M | 74 | 80 | TS | KRAS | G12A | 0.61 | Yes | Yes | |
17 | Liver | PD Carcinoma | F | 66 | 80 | TS | TP53 | R175H | 0.57 |